Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760840 | 1.00 | GABRA1 (0.41) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL28794719 | 0.82 | TAAR1 (0.40) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL6275225 | 0.82 | GABRA1 (0.57) | GABRA1GABRB2TAAR1IDO1ALDH1A1 | |
| SCHEMBL28528505 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL16941868 | 0.79 | GABRA1 (0.70) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL6870883 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL15352075 | 0.79 | GABRA1 (0.44) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL20516864 | 0.79 | TAAR1 (0.46) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL20560743 | 0.79 | GABRA1 (0.39) | GABRA1GABRB2GPR84TAAR1IDO1 | |
| SCHEMBL31145066 | 0.79 | GPR84 (0.42) | GABRA1GABRB2GPR84TAAR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2025-08-12 | — | — | US | disclosed |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240383911-A1 | AZAINDAZOLE MACROCYCLE COMPOUNDS AND USES THEREOF | BROADENBIO CO., LTD (CN) | 2024-11-21 | — | — | US | disclosed |
| WO-2024222712-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | RELAY THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4403558-A1 | AZAINDAZOLE MACROCYCLIC COMPOUND AND USE THEREOF | Broadenbio Co., Ltd (CN) | 2024-07-24 | — | — | EP | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2427444-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010129379-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2010-11-11 | — | — | US | disclosed |
| EP-2235007-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009085584-A1 | 6H-DIBENZ0 [B, E] OXEPINE DERIVED NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-0009787-B2 | PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION | BAYER AG (DE) | 1986-07-09 | — | — | EP | disclosed |
| EP-0009787-B1 | PROCESS FOR THE MONOHALOGENATION OF ALKYLBENZENES IN ALPHA POSITION | BAYER AG (DE) | 1982-01-13 | — | — | EP | disclosed |
| EP-0009787-A2 | Process for the monohalogenation of alkylbenzenes in alpha position | BAYER AG (DE) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384778-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | GABRA1 4487/4885GABRB2 4090/4885GPR84 3615/4885 |
| US-20240383911-A1 | AZAINDAZOLE MACROCYCLE COMPOUNDS AND USES THEREOF | FLT3, PDXK, FLT1 | GABRA1 1980/4885GABRB2 1501/4885GPR84 1992/4885 |
| US-12084447-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | GABRA1 3189/4885GABRB2 2029/4885GPR84 3435/4885 |
| US-20100286123-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, KCNJ2 | GABRA1 955/4885GABRB2 1373/4885GPR84 1781/4885 |
| US-12331056-B2 | SHP2 phosphatase inhibitors and methods of use thereof | PTPRCAP, PTPN22, PTPN1 | GABRA1 3189/4885GABRB2 2029/4885GPR84 3435/4885 |
| US-20240287059-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | GABRA1 4487/4885GABRB2 4090/4885GPR84 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.